Clinical trial
A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT02043288 is registered in ClinicalTrials.gov with Orient Europharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Lead sponsor
- Orient Europharma Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- December 31, 2019
- Enrollment
- 310 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.